Therefore, inhibiting MYC transcription indirectly via BET inhibitors or affecting transcription of Myc target genes by inhibiting CDK9 are promising strategies that have shown efficacy in Myc-driven cancers (Figure 3). This evidence concerns the gene CDK9 and cancer.